Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2017

Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer

L. Mignot
  • Fonction : Auteur
Thomas Bachelot
M.A. Mouret-Reynier

Résumé

Aim: Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy. Fertility issues are of great concern for them. However, little is known on ovarian damage during chemotherapy and its evolution during long-term follow-up. The Anti-Mü llerian hormone; Ovarian reserve; Amenorrhea aim of this study was to provide a detailed description of serum anti-Mü llerian hormone (AMH) evolution during chemotherapy and 24-month follow-up. Methods: This prospective cohort study was conducted in 250 patients, aged 18e39 years, diagnosed with breast cancer and treated with adjuvant/neoadjuvant chemotherapy. Each patient underwent blood AMH measurement at each chemotherapy cycle, and at 6, 12 and 24 months after chemotherapy. Menses occurrence was also recorded. Results: Mean basal AMH level was 4.19 AE 4.84 ng/mL, and was negatively correlated with age. Serum AMH level rapidly decreased in all patients after each chemotherapy cycle to undetectable levels in most of them, and slowly increased in 45% of the patients during the 24-month follow-up. AMH decrease was significantly associated with age and basal AMH level, but not with cyclophosphamide dose and tamoxifen use. The prevalence of chemotherapy-related amenorrhoea was 92.4% at the end of chemotherapy; women with amenorrhoea being significantly older and having lower basal AMH than women who resumed menses. Conclusions: Our study confirms rapid and deep ovarian reserve alteration in young women receiving chemotherapy for breast cancer, and shows moderate AMH recovery in some patients. Although AMH cannot alone predict fertility potential, these new data emphasise the need for post-treatment ovarian insufficiency follow-up, strongly support the use of fertility preservation strategies and may provide new tools for improved counselling.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02154804 , version 1 (13-06-2019)

Identifiants

Citer

A. Dezellus, P. Barriere, M. Campone, C. Lemanski, L. Vanlemmens, et al.. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. European Journal of Cancer, 2017, 79, pp.72-80. ⟨10.1016/j.ejca.2017.03.035⟩. ⟨inserm-02154804⟩
78 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More